Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

Circulation

Volumn 108, Issue 14, 2003, Pages 1682-1687

  Peters, Ron J G ^a   Mehta, Shamir R ^b   Fox, Keith A A ^c   Zhao, Feng ^b   Lewis, Basil S ^d   Kopecky, Steven L ^e   Diaz, Rafael ^h   Commerford, Patrick J ^h   Valentin, Vicent ^f   Yusuf, Salim ^b,g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MCMASTER UNIVERSITY   (Canada)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d CARMEL MEDICAL CENTER   (Israel)

^e MAYO CLINIC   (United States)

^f HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^g MCMASTER UNIVERSITY   (Canada)

^h NONE

Author keywords

Angina; Aspirin; Coronary disease; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART DEATH; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; STROKE; UNSTABLE ANGINA PECTORIS; VISUAL IMPAIRMENT;

ACUTE DISEASE; ANGINA, UNSTABLE; ASPIRIN; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; SYNDROME; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0141919739     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000091201.39590.CB     Document Type: Article

References (19)

1. Antithrombotic Triallists Collaboration. BMJ. 2002;324:71-86.
2. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S.
3. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction, 2002: Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893-1900.
5. Gilchrist IC, Berkowitz SD, Thompson TD, et al. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Am Heart J. 2002;144:73-80.
6. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
7. CURE study investigators. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial programme: rationale, design and baseline characteristics including a meta-analysis of the effects of thyenopyridines in vascular disease. Eur Heart J. 2000;21:2033-2041.
8. UK-TIA Study Group. United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: interim results. BMJ. 1988;296:316-320.
9. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor stroke. N Engl J Med. 1991;325:1261-1266.
10. Taylor DW, Barnett HJM, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet. 1999;353:2179-2184.
11. van Gijn J. Low doses of aspirin in stroke prevention. Lancet. 1999;353:2172-2173.
12. Kong DF, Hasselblad V, Kandzari DE, et al. Seeking the optimal aspirin dose in acute coronary syndromes. Am J Cardiol. 2002;90:622-625.
13. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990:336, 827-830.
14. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med. 1983;309:396-403.
15. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
16. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med. 1985;313:1369-1375.
17. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol. 1993;35:219-226.
18. Blankenship JC. Bleeding complication of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J. 1999;138:S87-S296.
19. Aguirre FV, Topol EJ, Ferguson JJ, et al for the EPIC investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 1995;91:2882-2890.